September 4, 2024 7:39am
There's always risks that drag down the sector
News: Cellectis (CLLS) published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment option for advance-stage triple negative breast cancer (TNBC) patients with limited therapeutic options.
Pre-open Indications: 3 Positive and 1 Negative Indications
There is no breadline for share pricing and fact-based intelligence! A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations.
Never leave an investor uninformed
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Wednesday: The pre-open Dow futures are DOWN -0.16% or (-64 points), the S&P futures are DOWN -0.39% or (-21 points) and the Nasdaq futures are DOWN -0.71% or (-130 points)
- Futures are falling on Wednesday,
- European markets lower,
- Asia-Pacific markets plunged
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
Tuesday: The Dow closed DOWN -626.15 points or -4.51%, the S&P closed DOWN -119.47 points or -2.12% while the Nasdaq closed DOWN -577.33 points or -3.26%
Tuesday’s advance/decline line ended with a negative at the close of 3 incliner, 29 decliners and 3 flats
Economic Data Docket: Job openings, July (8.1 million expected, 8.18 million previously); Factory orders, July (+4.6% expected, -3.3% previously); Durable goods orders, July final (9.9% previously) MBA Mortgage Applications, week ended Aug. 30 (+0.5% previously); Fed Beige Book release
From News in title:
- “In this article, Cellectis described its multi-layered CAR T-cell engineering strategy using TALEN® and synthetic biology to multi-armor CAR T-cells with synergistic functionalities to overcome the immunosuppressive tumor microenvironment (TME) of solid tumors. With this strategy, Cellectis demonstrates enhanced cytotoxic activity of MUC1 CAR T-cells armored with PD1KO, tumor-specific IL12 release and TGFBR2KO attributes, all of them catered towards the TNBC TME, in intravenous and intratumoral mouse models.
Tuesday’s RegMed Investors (RMi) Closing bell: “expectation = continued volatility, as I have written, share pricing satisfaction and disappointment will continue in alternating or leapfrogging sessions.” … https://www.regmedinvestors.com/articles/13599
Q3/24:
- September – 1 negative close
- August – I neutral, 10 positive and 11 negative closes
- July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context:
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Positive Indication:
Tuesday, Monday, Friday, Thursday as last Wednesday was a market holiday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Beam Therapeutics (BEAM) closed down -$2.28 after Monday’s holiday and Friday’s -$0.16 with a positive +$0.90 or +3.69% aftermarket
Cellectis SA (CLLS) closed down -$0.13 with NEWS and a positive +$0.05 or +2.19% aftermarket.
Regenxbio (RGNX) closed down -$0.88 after Monday’s holiday and Friday’s +$0.22 with a positive +$0.35 or +3.09% aftermarket
Negative Indications:
Tuesday, Monday, Friday, Thursday as last Wednesday was a market holiday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Alnylam Pharmaceuticals (ALNY) closed down -$8.91 after Monday’s holiday and Friday’s -$23.32 with a negative -$0.98 or -0.39% aftermarket.
The BOTTOM LINE: Stocks experienced a big dive Tuesday, the 1st session and 3rd day of September, with major indices trading in the red with weakness.
While … “Traders are bracing for further volatility in September, historically a weak month for equities, with many investors anticipating a pullback of 5% or more in the coming weeks. Still, some bullish investors expect any decline in stocks could be a buying opportunity.” <CNBC>
- Yesterday, Tuesday the S&P 500 slumped 2.1% Tuesday after a report showed U.S. manufacturing shrank again in August, weighed down by high interest rates, the Dow dropped -1.5% and the Nasdaq fell -3.3%. Treasury yields also sank in the bond market.
- The worse-than-expected manufacturing data raised worries about the slowing U.S. economy and upped the stakes for the all-important jobs report looming on Friday.
Ponder, Gradient Investments Portfolio Manager Keith Gangl … “reassures that the current sell-off is not cause for alarm. Despite a 2% pullback, markets are still up 19.5% for the year. He attributes the sell-off to profit-taking and, with the jobs report on the horizon, advises: "I think that everybody just needs to take a deep breath and kind of watch what's going on. It's normal for the markets to pull back, we'd like to go up straight 7 to 8% of the year, but it doesn't work that way.”
Think a game of shuts and ladders or sometimes monopoly … and follow RMi’s “interchanges” to gain profit moves or recoup losses – eat the popcorn and ponder ANY moves!
- Short on words, long on being Judicious!
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
